• TOC visit (7-14 days after EOT). The primary efficacy analysis will be performed on the per protocol population
• Subjects will be included in the per protocol analysis if they satisfy the following criteria of a valid course
• No other systemic antimicrobial agent (with the exception of one single dose of ceftriaxone in subjects with a gonococcal infection) was administered concomitantly with the study drug unless the subject was a treatment failure
• The study drug was given for a minimum of 72 hours (in case of clinical failure) or 8 full days (in case of success)
• The clinical evaluation at TOC visit must be available and different from “indeterminate”
• The subject was not given an immunosuppressive therapy, and had no neutropenia (<1000/mm3), no HIV infection with CD4 count < 200/mm3, no AIDS-defining event, and was not under HAART
• The diagnosis of uncomplicated pelvic inflammatory disease must have been confirmed
• Compliance with >= 80% of study medication administered, must be documented
• No protocol violations influencing the treatment efficacy must have been observed
• Study blind must have been maintained.

• Clinical response on treatment [ Time Frame: 4 to 7 days after start of treatment ] [ Designated as safety issue: Yes ]
• Biological response at TOC visit [ Time Frame: 7-14 days after completion of therapy ] [ Designated as safety issue: Yes ]
• Clinical response at TOC visit [ Time Frame: 7-14 days after completion of therapy ] [ Designated as safety issue: Yes ]
• Clinical and bacteriological responses at follow-up visit [ Time Frame: 28-42 days afterend therapy ] [ Designated as safety issue: Yes ]
• Necessity for modifying antibiotic therapy for PID [ Time Frame: from TOC up to end of follow up ] [ Designated as safety issue: Yes ]

• Clinical response during treatment (4 to 7 days after start of treatment)
• Bacteriological response at the TOC visit (7-14 days after the end of treatment)
• Clinical and bacteriological response at the Follow-up visit (28 to 42 days post-therapy)
• Clinical response at the TOC visit in subjects with bacteriologically documented infection.

To assess the efficacy and safety of oral moxifloxacin compared to oral levofloxacin plus oral metronidazole in uncomplicated pelvic inflammatory disease

• Drug: Avelox (Moxifloxacin, BAY12-8039)
• Drug: Levofloxacin & Metronidazole

Inclusion Criteria:

• Diagnosis of uncomplicated PID based on the absence of pelvic or tubo-ovarian abscess at pelvic ultrasound and/or laparoscopic examination.

Exclusion Criteria:

• Subjects with impaired liver and renal function; known hypersensitivity to study drugs, related compounds or any of the excipients.